HilleVax (NASDAQ:HLVX) Shares Gap Up to $12.02

HilleVax, Inc. (NASDAQ:HLVX)’s share price gapped up prior to trading on Friday . The stock had previously closed at $12.02, but opened at $12.58. HilleVax shares last traded at $11.99, with a volume of 1,768 shares trading hands.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of HilleVax in a research note on Thursday, March 21st.

HilleVax Stock Up 6.4 %

The business’s 50 day moving average is $15.79 and its 200-day moving average is $14.62. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.62 and a current ratio of 10.62. The stock has a market cap of $635.92 million, a price-to-earnings ratio of -4.21 and a beta of 0.65.

HilleVax (NASDAQ:HLVX) last released its earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.02. On average, sell-side analysts predict that HilleVax, Inc. will post -3.22 EPS for the current fiscal year.

Insider Activity at HilleVax

In other HilleVax news, CFO Shane Maltbie sold 3,576 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total value of $53,389.68. Following the transaction, the chief financial officer now directly owns 40,656 shares of the company’s stock, valued at approximately $606,994.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Robert Hershberg sold 11,597 shares of HilleVax stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $14.93, for a total transaction of $173,143.21. Following the transaction, the insider now owns 953,831 shares in the company, valued at $14,240,696.83. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Shane Maltbie sold 3,576 shares of HilleVax stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $14.93, for a total value of $53,389.68. Following the transaction, the chief financial officer now owns 40,656 shares in the company, valued at approximately $606,994.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,039 shares of company stock valued at $986,464,242. Corporate insiders own 29.30% of the company’s stock.

Hedge Funds Weigh In On HilleVax

Institutional investors have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C lifted its position in HilleVax by 20.3% during the third quarter. Deerfield Management Company L.P. Series C now owns 4,004,231 shares of the company’s stock worth $53,857,000 after buying an additional 675,000 shares in the last quarter. Monashee Investment Management LLC acquired a new stake in HilleVax during the third quarter worth $1,480,000. Adage Capital Partners GP L.L.C. acquired a new stake in HilleVax during the third quarter worth $2,374,000. Maven Securities LTD acquired a new stake in HilleVax during the third quarter worth $478,000. Finally, Swiss National Bank increased its stake in HilleVax by 47.2% during the third quarter. Swiss National Bank now owns 31,200 shares of the company’s stock worth $420,000 after acquiring an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 86.42% of the company’s stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.